It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aims
The pulmonary artery pulsatility index (PAPi) is a novel haemodynamic marker that has previously been shown to predict right ventricular dysfunction and mortality in patients with pulmonary hypertension and advanced heart failure. Utility of the PAPi in predicting outcomes post‐cardiac transplantation is unknown. The aim of this study was to compare the prognostic significance of PAPi against pulmonary vascular resistance (PVR) for the predication of morbidity and all‐cause mortality post‐transplantation.
Methods and results
All patients who underwent cardiac transplantation over a 6 year period were studied. Pre‐operative right heart catheter data was obtained. The PAPi was calculated as follows: (systolic pulmonary artery pressure [sPAP] − diastolic pulmonary artery pressure [dPAP])/right atrial (RA) pressure. One hundred fifty‐eight patients with a mean age of 49 ± 14 years were studied (43 with a pre‐transplant left ventricular assist device [LVAD]). Three patients were excluded due to missing data. In the non‐LVAD group, there was no significant difference in PAPi or PVR, nor was there any association with post‐operative outcome (including stratification by natural history sub‐type; all P > 0.05). In the LVAD group, there was no association with PAPi and post‐operative outcome; however, PVR was predictive of post‐operative mortality (mortality: 2.8 ± 1.3 WU vs. alive: 1.7 ± 0.7 WU; P = 0.005).
Conclusions
The PAPi was not able to discriminate mortality outcomes for patients post‐cardiac transplantation. Pulmonary vascular resistance remains a marker of mortality in an LVAD cohort bridged to transplant (central illustration).
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Emmanuel, Sam 1 ; Kotlyar, Eugene 1 ; Keogh, Anne 1 ; MacDonald, Peter 1 ; Muller, David 1 ; Hayward, Christopher 1 1 Department of Cardiology, St Vincent's Hospital, Sydney, New South Wales, Australia, St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia
2 Department of Cardiology, St Vincent's Hospital, Sydney, New South Wales, Australia, St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia, Department of Cardiology, Royal North Shore Hospital, Sydney, New South Wales, Australia





